Q-omics provides the consensus-scored CTBP2P9 profile across patient tissues and cancer cell-line models. CTBP2P9 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CTBP2P9 is differentially expressed in 1, with the highest sampling consensus in ESCA. Additionally, CTBP2P9 RNA expression shows 2,873 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight UCEC, ESCA, and DLBC as cancer lineages where CTBP2P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTBP2P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTBP2P9 survival associations across molecular data types. CTBP2P9 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTBP2P9 RNA expression–survival associations across cancer types. High CTBP2P9 expression shows unfavorable associations in UCEC, THYM, MESO, BLCA, GBM and PCPG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CTBP2P9 RNA expression.
This table summarizes CTBP2P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for CTBP2P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTBP2P9 shows lower tumor expression in ESCA. The ESCA box plot shows higher CTBP2P9 RNA expression in normal versus tumor tissue (log2 FC = −0.058, t-test p = .002).
This table shows molecular features associated with CTBP2P9 in patient tissues and cancer cell lines. In patient samples, CTBP2P9 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
